Skip to Content

Press Releases

Date Title Additional Format
Jun 06, 2022
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
–   Patient 1 showed blood glucose time-in-range change from 40.1% on 34.0 units per day of exogenous insulin at baseline to 99.9% and insulin independence at Day 270 – –   Patient 2 showed blood glucose time-in-range change from 35.9% on 25.9 units per day of exogenous insulin at baseline to 51.9%
Jun 02, 2022
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
 - Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation – BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics
May 31, 2022
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
BOSTON --(BUSINESS WIRE)--May 31, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell‑derived, fully differentiated
May 18, 2022
Suketu Upadhyay Elected to Vertex Board of Directors
BOSTON --(BUSINESS WIRE)--May 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyay   has been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the
May 17, 2022
Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies
-New 344,000 square foot cell and genetic therapies research and manufacturing facility to be built- -Facility to support continued R&D growth- BOSTON --(BUSINESS WIRE)--May 17, 2022-- At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex
May 17, 2022
Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
 – Vertex grant to JDRF supports efforts to improve clinical trial diversity in type 1 diabetes – – The Vertex Foundation grant supports the Mass General Comprehensive Sickle Cell Disease Treatment Center – – Additional Vertex Foundation grant to Year Up to support health care workforce training –
May 05, 2022
Vertex Reports First Quarter 2022 Financial Results
— Product revenues of $2.10 billion , a 22% increase compared to Q1 2021 — — Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion — — Mid- and late-stage clinical pipeline now spans 6 disease areas — BOSTON --(BUSINESS WIRE)--May 5, 2022-- Vertex Pharmaceuticals
May 02, 2022
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
-  Clinical proof-of-concept achieved based on positive data from the first two patients dosed at half the target dose of cells in Part A of Phase 1/2 study - - First patient achieved insulin independence at Day 270; positive data in second patient; third patient has received full target dose with
Apr 21, 2022
Vertex to Announce First Quarter 2022 Financial Results on May 5
BOSTON --(BUSINESS WIRE)--Apr. 21, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
Apr 20, 2022
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
-Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA ® - - Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments- BOSTON --(BUSINESS WIRE)--Apr. 20, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has
Mar 31, 2022
Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
-  Treatment with the NaV1.8 inhibitor VX-548 met the primary endpoint in both Phase 2 proof-of-concept acute pain studies following abdominoplasty or bunionectomy surgery - - VX-548 was generally well tolerated - - Results further highlight NaV1.8 as a new mechanism that could create an
Mar 26, 2022
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
- With this reimbursement agreement in place, more than 2,200 people with CF will have PBS -funded access to TRIKAFTA ® , including more than 700 who will now have access to a CFTR modulator therapy for the first time - LONDON --(BUSINESS WIRE)--Mar. 26, 2022-- Vertex Pharmaceuticals Incorporated
Mar 22, 2022
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
– Single pivotal trial to initiate later this month targets the broad patient population with two APOL1 mutations and proteinuric kidney disease – – Pathway for accelerated approval using an interim analysis at Week 48 of eGFR slope, supported by reduction in proteinuria – – Final analysis
Mar 01, 2022
Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8
BOSTON --(BUSINESS WIRE)--Mar. 1, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen’s 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:50 p.m. ET . A live webcast of management's remarks will be available through Vertex
Jan 26, 2022
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
-Full year product revenues of $7.57 billion , a 22% increase compared to full year 2020- -Company provides full year 2022 product revenue guidance of $8.4 to $8.6 billion - - Advancing broad clinical pipeline across six disease areas; multiple programs in mid- and late-stage development with
Jan 18, 2022
Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
BOSTON ----(BUSINESS WIRE)--Jan. 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
Jan 11, 2022
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
- More than 1,500 children now eligible to receive a treatment targeting the underlying cause of cystic fibrosis for the first time - LONDON --(BUSINESS WIRE)--Jan. 11, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for
Jan 04, 2022
Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
BOSTON --(BUSINESS WIRE)--Jan. 4, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:00 a.m. ET . A live webcast of management's remarks will be available
Dec 01, 2021
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
– Treatment with VX-147 led to a statistically significant, substantial and clinically meaningful mean reduction in proteinuria of 47.6% at 13 weeks compared to baseline and was well tolerated – – Results provide clinical proof of concept for the first genetically targeted approach to treating
Nov 19, 2021
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
– With this reimbursement agreement approximately 700 people with cystic fibrosis now have access to a CFTR modulator therapy for the first time – LONDON --(BUSINESS WIRE)--Nov. 19, 2021-- Vertex Pharmaceuticals Incorporated   (Nasdaq: VRTX) today announced that the Spanish government has approved
Displaying 21 - 40 of 744